Articles tagged with Vaccine Development
Researchers have discovered a promising new treatment and vaccine for Alzheimer's disease by targeting the toxic form of amyloid beta protein. Both the antibody-based treatment and the protein-based vaccine reduced Alzheimer's symptoms in mouse models, offering hope for potential transformation in patient lives.
Researchers from the University of Copenhagen have discovered that naturally acquired immunity to malaria works differently than immunity following vaccination. The immune system uses natural killer cells to fight the parasite, which is more tailored to the disease than other typical infections.
The BBV152 COVID-19 vaccine demonstrated robust antibody response and induced 77.8% protection against symptomatic COVID-19 in a phase 3 trial. No severe vaccine-related adverse events or deaths were reported among participants.
A gene-silencing therapy harnessing nanoparticles called small extracellular vesicles (sEVs) for drug delivery has protected against Zika virus transmission in pregnant mice to the mouse fetuses. The treatment reduced fetal neurological damage, including virus-induced brain shrinkage.
A new study reveals that memory T helper cells can work with memory B cells to effectively defend the body against chronic viruses. This finding has direct relevance to developing new vaccines for HIV and hepatitis C, as it suggests a more sustained immune response.
An international research team discovered that intestinal bacteria can distribute their metabolic products throughout the body via the bloodstream using membrane vesicles. The study found that these vesicles can overcome the blood-brain barrier and enter brain cells, suggesting a new method for delivering drugs or vaccines.
A new protein-based vaccine design has been developed that elicits strong immune responses in mice and does not require cold storage. The technology targets antigen-presenting cells directly, potentially filling global vaccination gaps and offering a manufacturing advantage over existing COVID vaccines.
A study of 780,225 Veterans found that protection against COVID-19 declined by 38.8% from February to October 2021 for all vaccine types, with overall vaccine protection declining from 87.9% to 48.1%. Vaccination remained protective against death in those who became infected during the Delta surge.
A new report highlights the alarming global impact of Group B streptococcus, which can lead to up to 150,000 infant deaths annually. Maternal vaccination is seen as a cost-effective solution to reduce this toll, with significant health benefits in all regions.
Researchers at Duke University and UNC-Chapel Hill have identified a new antibody that can block infections and minimize symptoms against a broad array of coronaviruses, including SARS-CoV-1 and SARS-CoV-2. The antibody was tested in animal models and found to be effective in protecting mice against developing severe lung symptoms.
A study of 8,889 vaccinated patients and 88,898 unvaccinated patients found the Ad26.COV2.S vaccine to be effective in reducing SARS-CoV-2 infection. The results support mass vaccination efforts globally amid variant spread.
Researchers at Johns Hopkins Medicine found that antibody levels against SARS-CoV-2 stay higher in people who were infected by the virus and then received protection from mRNA vaccine compared to those who only got vaccinated. A longer interval between virus exposure and first vaccine dose may enhance antibody response.
Researchers at University of Queensland successfully protected mice from COVID-19 using a US-developed vaccine candidate delivered via a pocket-sized, pain-free applicator. The vaccine produced strong immune responses and neutralized multiple variants, including UK and South Africa variants.
A new vaccine has shown significant protection against Valley fever in dogs, offering hope for a potential human vaccine. The study found that two doses provided high levels of protection against the fungal disease.
Researchers developed a device that uses light to manipulate and isolate individual viruses, enabling precise diagnosis, treatment, and study of viruses. The device has the potential to aid in vaccine development and research on SARS-CoV-2 virus, allowing for targeted analysis of specific virus mutants.
Researchers discovered that a lower dose of the first shot, followed by a full-dose booster, significantly improved SARS-CoV-2 vaccine potency in mice. This approach, which involves an extended prime-boost interval, may lead to more robust and durable immune responses.
A recent study published in eLife reveals that the shape of the respiratory syncytial virus (RSV) plays a crucial role in determining infection outcomes. Researchers found that RSV viruses change from long, rod-shaped particles to more rounded ones during infection, which affects the activation of complement proteins by the immune system.
Researchers at Georgia Tech and Emory University have developed an innovative method for delivering vaccines, including those for COVID-19, using a handheld electroporator. The device is powered by a BBQ lighter and uses microneedle technology to reduce the complexity and cost of vaccine delivery.
Researchers compared immune responses elicited by three COVID-19 vaccines over an eight-month follow-up period. The mRNA vaccines showed high peak antibody responses that declined sharply, while the single-shot Ad26 vaccine induced lower initial antibody responses but stable levels over time.
A study by Northwestern University scientists has shown that coronavirus vaccines and prior infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines.
Researchers developed a program to target vaccinations using digital contact tracing technology, which can almost halve the number of vaccines required to bring the pandemic under control. The new program prioritizes individuals with the most contacts for vaccinations while keeping personal data private.
A team of researchers developed a new nanomechanical technique to fast-track the detection of COVID-19 variants. The method provides real-time insights into infection immunity and enables direct classification of variant-binding properties.
Researchers in Japan developed a vaccination approach that promotes the production of antibodies neutralizing SARS-CoV-2 and other coronaviruses. The new strategy involves genetically engineering the spike protein receptor-binding domain to shield its head region, boosting antibody production against the core region.
The University of Kansas Chemical Biology of Infectious Disease Center has received a five-year, $11.35 NIH COBRE grant to expand research on next-generation drug therapies for infectious disease. The center will build on previous accomplishments to push forward biological research and foster a collaborative research network.
Researchers at UToledo have developed a protein-based vaccine that promotes a strong immune response, effectively treating rheumatoid arthritis and improving bone quality. The findings suggest long-term benefits following immunization.
Researchers developed an Internet information system, virusMED, to provide a comprehensive picture of viruses' most important regions. The database contains over 800 strains from 75 different families, including SARS-CoV-2, influenza, Ebola, and HIV-1, enabling scientists to respond quickly and effectively against the next pathogen.
Researchers identified five specific mutations prevalent in Delta Plus infections compared to Delta, highlighting the need for expanded antiviral tools. The findings provide clues on how the virus mutates and evade antibodies produced from previous COVID-19 infections or vaccinations.
Researchers developed a mathematical model to study the action of SARS-CoV-2, enabling the examination of individual virus particles and their spikes. This analysis can help fine-tune prevention and treatment by providing insights into viral load, spike distribution, and cell infection potential.
A global collaboration has identified three groups of antibodies resistant to mutations in the SARS-CoV-2 Spike protein, which could target vulnerable sites on the protein. The study provides a framework for selecting durable antibody cocktails for COVID-19 treatment and will guide the development of more effective antibody therapies.
Researchers have developed a microneedle patch that delivers a COVID-19 DNA vaccine into the skin, causing strong immune responses in cells and mice. The patch can be stored at room temperature for over 30 days, making it an important tool for global COVID-19 vaccine distribution.
Patients with cancer show strong immune response to COVID-19 vaccination without increased side effects. A third booster dose may further increase protection.
Researchers at the University of Illinois found that antibodies from people infected with the original COVID-19 strain do not effectively bind to newer variants. This has implications for vaccine efficacy and the design of possible boosters.
Researchers at the University of Alabama at Birmingham found that SARS-CoV-2 viruses grown in successive generations exhibit increased infectivity, binding to heparan sulfate, and reduced virulence. The study suggests that evolved strains may be used as a basis for development of stable live attenuated vaccines.
A two-dose Ebola vaccine regimen has been found to be safe, well-tolerated, and produce a strong immune response in people over 1 year old. The study also supports the use of this regimen for Ebola virus disease prevention in children and adults.
A recent expert review published in The Lancet concludes that COVID-19 vaccine efficacy against severe disease is high, but booster doses for the general population are not necessary. Vaccination remains highly effective against severe disease, including variants like delta and alpha.
A predictive model estimated that cervical cancer may be eliminated in the US by 2030 in low-poverty areas, but not until 2044 in high-poverty areas. Health care disparities are a major contributor to these disparities, including lower vaccination rates and higher prevalence of cancer-causing HPV types.
Researchers at the University of California - San Diego have developed COVID-19 vaccine candidates made from plant viruses and bacteriophages, which can be stored and shipped without refrigeration. These vaccines trigger high production of neutralizing antibodies in mice, offering a potential solution for global distribution efforts.
Researchers are developing a vaccine to prevent oxycodone use disorder, which affects half of those treated with existing medications. The experimental vaccine has shown promise in preclinical studies and is now being tested in a phase 1a/1b clinical trial at Columbia University.
Researchers at King's College London found that double vaccination significantly reduces the risk of Long COVID, with a 49% lower likelihood of contracting the virus. Fully vaccinated individuals also experience milder symptoms, fewer hospitalizations, and a lower burden of acute symptoms.
A novel COVID-19 vaccine candidate demonstrates high efficacy in preclinical models by stimulating the immune system and inducing a robust neutralizing antibody response. The vaccine protects against reinfection and provides better protection than natural immunity, making it a potential supplement to existing vaccines.
The International Vaccine Institute (IVI) has initiated a Phase II/III clinical trial for the Bharat Biotech Chikungunya vaccine candidate BBV87, evaluating its safety and immunogenicity in healthy adults across five countries. The study aims to develop an affordable vaccine with the aim of achieving WHO prequalification.
Researchers at Purdue University and Houston Methodist have developed a novel TB vaccine formulation that enhances T cell responses to combat tuberculosis. The new vaccine uses autophagy-mediated antigen presentation, showing promising results in improving immune response.
Researchers at the University of Maine are developing more effective, safe, and sustainable fish vaccines using nanocellulose to protect Atlantic salmon against lethal pathogens. The goal is to reduce vaccine costs and side effects while increasing effectiveness.
Researchers at Washington University School of Medicine found that COVID-19 vaccination antibodies are effective against the delta variant. The study analyzed antibodies generated by people in response to the Pfizer vaccine and found that 12 out of 13 antibodies recognized both alpha and delta variants, while one antibody failed to rec...
A large-scale population-based study confirms that COVID-19 vaccines far outweigh the risk of Bell's palsy. The study found a small increased risk of Bell's palsy associated with CoronaVac vaccination, but not with BNT162b2.
Researchers at Berkeley Lab have made significant breakthroughs in developing a highly effective COVID-19 antibody therapy and an efficient thermoelectric system that can convert waste heat to electricity. The new antibody, S309, has been shown to neutralize all known SARS-CoV-2 strains and may be more difficult for new mutants to escape.
A new research strategy enhances COVID-19 vaccine effectiveness by providing 'border protection' immunity in the nose, mouth and blood. The approach involves suppressing an enzyme that breaks down both pathogens and immune cells, resulting in a robust antibody response and improved protection against infections.
Researchers developed a protein-based COVID-19 vaccine that mimics the SARS-CoV-2 virus shape, eliciting both antibody and T cell responses. The vaccine, using polymersomes decorated with multiple copies of the receptor binding domain antigen, shows promise for longer-lasting immunity.
SK bioscience's GBP510 vaccine candidate has shown promising safety and immunogenic response in Phase I/II clinical trials. IVI will partner with SK on global Phase III trials to accelerate development and WHO approval of the vaccine.
A Dartmouth research team led by Glyn Elwyn is testing interactive educational approaches to boost vaccine confidence among unvaccinated long-term care workers. The study aims to measure vaccine confidence, knowledge, and trust in the COVID-19 vaccines.
Researchers developed a θ-SIR model to simulate the impact of SARS-CoV-2 strains and vaccines on COVID-19 propagation. The model estimates that insufficient vaccination rates can lead to new waves, even with effective reproduction numbers below 1.
A new study published in Nature Medicine reveals that willingness to get a COVID-19 vaccine is higher in developing countries, with personal protection being the main reason for acceptance. Concern about side effects was the most common reason for vaccine hesitancy, but health workers were considered trusted sources of information.
Researchers developed a biomaterial-based infection vaccine (ciVAX) approach to combat infectious diseases. ciVAX vaccines combine two technologies that capture immunogenic antigens from pathogens and reprogram the immune system, offering potential solutions for sepsis prophylaxis, pandemic threats, and biothreats.
Experts debate whether COVID-19 vaccination should be delayed in children due to unclear benefits and risks. Vulnerable people worldwide should be prioritized instead, but some argue that children should not be disadvantaged.
A new study found that only 20 out of 51 US states included health equity committees in their COVID-19 vaccine distribution plans, with only 8 representing minority groups. The study highlights the need for standardized processes to address existing healthcare disparities and ensure equitable access to vaccines.
Researchers at TUM created a low-cost, automated rapid test for detecting SARS-CoV-2 antibodies with high sensitivity and specificity. The test can determine antibody concentrations and has the potential to answer questions about corona immunity, vaccinations, and disease progression.
Researchers have uncovered a novel strategy employed by MRSA to evade the immune response, causing toxic effects on white blood cells. A mutated protein-based vaccine shows promise in preventing such toxicity, suggesting a potential cure for deadly MRSA infections.
Researchers at UNC-Chapel Hill developed a universal vaccine that protects against multiple coronaviruses, including COVID-19 and SARS. The hybrid vaccine effectively generated neutralizing antibodies against various spike proteins, preventing infection and lung damage in mice.
Vaccine developers suggest that documented side effects are a byproduct of an effective immune response. The authors argue that fatigue and headache after vaccination should be viewed positively as a necessary step towards herd immunity.
A research team at POSTECH has created a multivalent, adjuvant-free vaccine against various strains of avian influenza. The vaccine uses green vaccine technology to produce bacteria-like particles that elicit strong immune responses in mice and chickens.